欧盟评估非转基因埃默森罗萨氏菌菌株FGB生产的含有三种酶活性的食品酶的安全性

核心提示：2026年6月17日，欧盟食品安全局就一种含内切-1,3（4）-β-葡聚糖酶、内切-1,4-β-木聚糖酶和纤维素酶活性的食品酶的安全性评价发布意见。……（世界食品网-www.shijieshipin.com）

　　 2026年6月17日，欧盟食品安全局就一种含内切-1,3（4）-β-葡聚糖酶、内切-1,4-β-木聚糖酶和纤维素酶活性的食品酶的安全性评价发布意见。
　　据了解，这种食品酶是由非转基因埃默森罗萨氏菌（Rasamsonia emersonii）菌株FGB生产的，旨在用于4种食品生产过程。

　　经过评估，专家小组认为，在预期的使用条件下，不能排除通过饮食接触引起过敏反应的风险，但这种情况发生的可能性很低。根据所提供的数据，小组得出结论，该食品酶在预期的使用条件下不会引起安全问题。部分原文报道如下：

　　The food enzyme containing endo-1,3(4)-β-glucanase (3-(1,3;1,4)-β-d-glucan 3(4)-glucanohydrolase; EC 3.2.1.6), endo-1,4-β-xylanase (4-β-d-xylan xylanohydrolase; EC 3.2.1.8) and cellulase (4-(1,3;1,4)-β-d-glucan-4-glucanohydrolase EC 3.2.1.4) is produced with the non-genetically modified Rasamsonia emersonii strain FGB by DSM Food Specialties B.V. The food enzyme is considered free from viable cells of the production organism. It is intended to be used in four food manufacturing processes. Dietary exposure to the food enzyme–total organic solids (TOS) was estimated to be up to 0.226 mg TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 85 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 376. A search for the homology of the amino acid sequences of the food enzyme to known allergens was made and matches with two respiratory allergens were found. The Panel considered that a risk of allergic reactions upon dietary exposure to the food enzyme cannot be excluded, but that the likelihood is low. based on the data provided, the Panel concludes that this food enzyme does not give rise to safety concerns, under the intended conditions of use.